Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 41927 | 12.15 |
09:34 ET | 30340 | 12.12 |
09:36 ET | 8625 | 12.06 |
09:38 ET | 16309 | 12.005 |
09:39 ET | 86109 | 11.91 |
09:41 ET | 58338 | 11.895 |
09:43 ET | 36714 | 11.94 |
09:45 ET | 21543 | 11.915 |
09:48 ET | 26120 | 11.955 |
09:50 ET | 17756 | 11.965 |
09:52 ET | 27879 | 11.935 |
09:54 ET | 27770 | 11.905 |
09:56 ET | 44991 | 11.955 |
09:57 ET | 25148 | 11.98 |
09:59 ET | 29767 | 12.005 |
10:01 ET | 45374 | 11.97 |
10:03 ET | 137316 | 12.0013 |
10:06 ET | 56061 | 11.99 |
10:08 ET | 69698 | 12.01 |
10:10 ET | 22398 | 11.995 |
10:12 ET | 16850 | 12 |
10:14 ET | 22072 | 12.07 |
10:15 ET | 43727 | 12.05 |
10:17 ET | 21189 | 12.05 |
10:19 ET | 27087 | 12.075 |
10:21 ET | 28301 | 12.07 |
10:24 ET | 23885 | 12.035 |
10:26 ET | 22366 | 12.015 |
10:28 ET | 6640 | 12.025 |
10:30 ET | 17982 | 12.035 |
10:32 ET | 23005 | 12.035 |
10:33 ET | 27466 | 12.045 |
10:35 ET | 15482 | 12.06 |
10:37 ET | 30084 | 12.07 |
10:39 ET | 18711 | 12.075 |
10:42 ET | 18718 | 12.05 |
10:44 ET | 13089 | 12.045 |
10:46 ET | 6608 | 12.035 |
10:48 ET | 18580 | 12.025 |
10:50 ET | 123351 | 12.01 |
10:51 ET | 19261 | 11.995 |
10:53 ET | 25915 | 11.96 |
10:55 ET | 6425 | 11.955 |
10:57 ET | 88584 | 11.99 |
11:00 ET | 24696 | 11.94 |
11:02 ET | 25726 | 11.98 |
11:04 ET | 2511 | 11.99 |
11:06 ET | 11166 | 12.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.9B | 2.2x | --- |
Corcept Therapeutics Inc | 4.4B | 37.6x | +9.80% |
Ligand Pharmaceuticals Inc | 1.9B | 47.2x | -12.71% |
Harrow Inc | 1.6B | -49.1x | --- |
Ocular Therapeutix Inc | 1.4B | -8.3x | --- |
Immunocore Holdings PLC | 1.7B | -32.2x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.9B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.2x |
Price/Sales (TTM) | 56.1 |
Price/Cash Flow (TTM) | 1.9x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.